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Introduction. The incidence of coronary heart disease (CHD) is progressively 
increasing worldwide, despite active medical and preventive measures [1]. 
Furthermore, the proportion of endocrinopathies in the society is also increasing, 
more than 50% of which are diseases of the thyroid gland, primarily autoimmune 
thyroiditis (AIT) [2]. Modern scientific researches have established that chronic 
systemic inflammation (CSI) is of paramount importance in the development and 
progression of atherosclerosis, which forms the basis of coronary heart disease [3]. 
Apoptosis of thyrocytes in AIT also occurs with the participation of proinflammatory 
cytokines (CK) [4].Therefore, it is expedient to study the markers of CSI in order to 
assess the course of these diseases and the effectiveness of therapeutic measures [5]. 
The aim of our research was to study the dynamics of CSI markers in patients 
with coronary heart disease concurrent with AIT under the influence of polyphenol 
resveratrol [6]. 
Materials and methods. 115 patients of both sexes aged 48-69 participated in 
the study: 85 patients with coronary heart disease: stable exertional angina, FC II, CH 
0-I and 30 patients with additional AIT diagnosis, euthyroid variant of the course, 5 
of which – medically corrected subclinical hypothyroidism. 30 patients with coronary 
heart disease (study group 1) and 30 patients with concomitant AIT (study group 2) 
received standard resveratrol 100 mg daily for 2 months. 55 patients with CHD 
formed the comparison group. In all patients, the level of CK – tumor necrosis factor 
(TNFα), interleukin-1β (IL-1β) and IL-10 in blood serum was determined before the 
initiation of treatment and after 2 months  by the immune enzyme method, the 
fibrinogen content (FG) in blood plasma by weight method, the content of circulating 
endothelial microparticles (CEM) with surface antigens CD32 and CD40 by flow 
cytofluorimetry using monoclonal antibodies and expression of the matrix ribonucleic 
acid gene (mRNA) of kappa B inhibitor (IkB) nuclear kappa B transcript (NF-kB) by 
real-time polymerase chain reaction (Real-time PCR) using a relative Ct method for 
data analysis [7, 8]. 
Results. In patients of all study groups, an increased content of CK was 
revealed, an increase in the number of CEM CD32+CD40+ (p <0.05), indicating 
inflammatory activation and endothelium dysfunction. In 34% of patients with 
coronary heart disease and 25% of patients with coronary heart disease concurrent 
with AIT, an increase in the content of FG was observed. Expression of mRNA IkB 
(2-ΔС) in the study groups was not significantly different. Under the influence of 
resveratrol, the IL-1β content decreased (6.98 + 2.52 pg / ml versus 10.05 + 3.67 pg / 
ml, p = 0.0022), TNFα (7.28 + 2, 18 pg / ml versus 9.69 + 1.63 pg / ml, p = 0.013), 
there was a tendency to decrease in the content of IL-10 (p = 0.0546). In group 2, the 
content of IL-1β (6.87 + 2.13 pg / ml versus 10.06 + 2.79 pg / ml, p = 0.0011) and 
TNFα (7.94 + 3, 43 pg / ml versus 10.54 + 2.42 pg / ml, p = 0.00045) significantly 
decreased, while the content of IL-10 remained unchanged (p = 0.455). In the 
comparison group, there were no reliable changes in the content of CK. Under the 
influence of resveratrol, there was a decrease in CEM CD32+CD40+ in both group 1 
(p = 0.038) and group 2 (p = 0.035), indicating an improvement in the function of the 
endothelium. In the comparison group, this indicator did not change (p = 0.547). In 
patients of all groups, a reliable decrease in the content of FG in blood plasma was 
detected (p <0.01). Expression of mRNA IkB decreased in group 2 (0.0101 + 0.0062 
vs. 0.0207 + 0.0153, p = 0.031), which was calculated by the method 2-ΔΔСt -2.006 + 
0.53, and did not significantly change in group 1 (p = 0.884) and in the comparison 
group (p = 0.570). 
Conclusion. Thus, in patients with coronary heart disease and concurrent with 
AIT, elevated levels of CSI and inflammatory activation of the endothelium were 
determined, while comorbidity determined a more significant degree of impairment. 
The use of resveratrol polyphenol contributed to the decrease in the levels of 
proinflammatory cytokines, the content of acute phase reactant of inflammation of 
FG in the blood, and provided an endothelioprotective effect. In comorbidity of CHD 
and AIT, resveratrol, along with the above-mentioned effects, caused a decrease in 
NF-kB-mediated signaling, which plays a leading role in the expression of 
inflammation genes. 
Prospects for further research. The obtained results are the basis for the 
development and implementation of treatment regimens focused on CSI, using 
resveratrol in CHD, AIT and in comorbid conditions. 
Recommendations. It is expedient to use inflammatory markers to assess the 
course of CHD, AI and in case of their combination. The application of resveratrol as 
an anti-inflammatory agent in the comprehensive therapy of these diseases is 
pathogenetically feasible and effective. 
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